Web Content Viewer

Actions

Ultrathin Orsiro DES confirms its efficacy and safety profile out to 5 years




Efficacy - Target Lesion Failure1 (TLF) // All population




Safety – Definite or Probable Stent Thrombosis6 (ST) // All population




Efficacy – Target Lesion Failure1 (TLF) // Sub-groups


Two independent studies show low TLF rates out to 5 years – even in high risk subgroups.



1. Composite of cardiac death, target vessel Q-wave or non-Q wave Myocardial Infarction (MI), Emergent Coronary Artery Bypass Graft (CABG), clinically driven Target Lesion Revascularization (TLR);
2. Windecker S, Haude M, Neumann FJ, et al. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial. Circ Cardiovasc Interv. 2015 Feb;8(2):e001441. DOI: 10.1161/CIRCINTERVENTIONS.114.001441;
3. Slagboom T BIOFLOW-II 5Y data, Poster Presented at: EuroPCR 2018; MAY 24, 2018; Paris, France; ClinicalTrials.gov: NCT01356888;
4. Waltenberger J, Brachmann J, van der Heyden J, et al. Real-world experience with a novel biodegradable polymer sirolimus-eluting stent: twelve-month results of the BIOFLOW-III registry. EuroIntervention. 2016 Feb 11(10):1106-10. DOI: 10.4244/EIJY15M03_08;
5. Waltenberger J BIOFLOW-III 5Y data; Poster Presented at: EuroPCR 2018; MAY 24, 2018; Paris, France; ClinicalTrials.gov: NCT01553526;
6. ST as per ARC definition;
7. Waltenberger J BIOFLOW-III 5Y data; Poster Presented at: tct 2017; October 31, 2017; Denver, USA; ClinicalTrials.gov: NCT01553526.
Xience and Xience Prime are registered trademarks of Abbott Cardiovascular Systems Inc.

${loading}